Orient Bio

Orient Bio FCF Growth

The Year-over-Year Free Cash Flow Growth of Orient Bio (002630.KS) as of Oct 21, 2026 is 113.54 %. In the previous year, Year-over-Year Free Cash Flow Growth was -242.57 % — a change of -146.81% (higher).

FCF Growth

113.54 %

YoY

-146.81%

Last updated:

Year-over-Year Free Cash Flow Growth of Orient Bio is 2026 113.54 % . Year-over-Year Free Cash Flow Growth of Orient Bio was 2025 -242.57 % . It decreases by -146.81% higher compared to the previous year.

The Orient Bio FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2019
-457.64 KRW
Jan 1, 2020
83.17 KRW
Jan 1, 2021
282.55 KRW
Jan 1, 2022
-98.34 KRW
Jan 1, 2023
379.84 KRW
Jan 1, 2024
319.89 KRW
Jan 1, 2025
-242.57 KRW
Jan 1, 2026
113.54 KRW
The Orient Bio FCF Growth history
YEARFCF GrowthYoY
113.54 %-146.81%
-242.57 %-175.83%
319.89 %-15.78%
379.84 %-486.24%
-98.34 %-134.81%
282.55 %+239.70%
83.17 %-118.17%
-457.64 %-974.43%
52.34 %+124.71%
23.29 %-108.13%
-286.42 %-597.53%
57.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Year-over-Year Free Cash Flow Growth of Orient Bio is 113.54 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Orient Bio since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Orient Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Orient Bio

All Key Metrics — Orient Bio